AVANT to Host Conference Call Today, April 16, 2008, at 5:00 PM to Discuss CDX-110 Partnership with Pfizer
16 Abril 2008 - 3:41PM
Business Wire
AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) will hold a
conference call today at 5:00 PM ET to discuss today�s announcement
of an exclusive worldwide licensing and development agreement
between AVANT, acting through its wholly-owned subsidiary Celldex
Therapeutics, Inc., and Pfizer for CDX-110. CDX-110, a therapeutic
cancer vaccine candidate, is in Phase 2 development for the
treatment of glioblastoma multiforme (GBM). To access the live
call, dial 866-383-8009 (within the United States) or 617-597-5342
(outside the United States). The passcode for participants is
83919284. The call will also be available live on the Company�s
website www.avantimmune.com in the Investor Information, Investor
Overview section. A replay will be available approximately two
hours after the live call until April 23, 2008. To access the
replay, dial 888-286-8010 (within the United States) or
617-801-6888 (outside the United States). The replay passcode is
71323547. The replay will also be available on the Company�s
website www.avantimmune.com. About AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics and Celldex Therapeutics combined during
the first quarter of 2008. AVANT is a NASDAQ-listed company
discovering and developing innovative vaccines and targeted
immunotherapeutics for the treatment of cancer, infectious and
inflammatory diseases. AVANT focuses on the use of tumor-specific
targets and human monoclonal antibodies (mAbs) to precisely deliver
therapeutic agents through its novel �targeted immunization�
approach. In addition, AVANT is exploiting its access to
proprietary human antibody technology for development of
therapeutic monoclonal antibodies (mAbs). AVANT�s deep product
pipeline consists of products in varying stages of development.
Identification of the potential of EGFRvIII in cancer diagnosis,
prevention and therapy was based on the collaborative efforts of
Dr. Bert Vogelstein and Dr. Albert Wong at Johns Hopkins University
and Dr. Darell Bigner at Duke University. Application of this
discovery toward the development of the CDX-110 vaccine was further
advanced by Dr. John Sampson and his colleagues at the Duke
University Brain Tumor Center in collaboration with Dr. Amy
Heimberger at the MD Anderson Cancer Center. AVANT also has several
product candidates in its development pipeline including: CDX-1307,
a product based on its proprietary APC Targeting Technology�, which
is in two Phase 1 clinical trials for patients with advanced
pancreatic, bladder, breast and colon cancer; TP10, a complement
inhibitor, in development for transplantation and other
indications; and Three candidates based on its oral,
rapidly-protecting, single-dose and temperature-stable vaccine
technology, including combination vaccines for travelers, the
military and global health needs. AVANT has three commercialized
products, including Rotarix� (partnered with GSK) for the
prevention of rotavirus infection and two human food safety
vaccines for reducing salmonella infection in chickens and eggs.
For more information on AVANT or Pfizer or please visit
www.avantimmune.com or www.pfizer.com.
Avant Immunotherapeutics (MM) (NASDAQ:AVAN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Avant Immunotherapeutics (MM) (NASDAQ:AVAN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Avant Immunotherapeutics (MM) (NASDAQ): 0 recent articles
Más de AVANT Immunotherapeutics, Inc. ArtÃculos de Noticias